Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Fox Corp Class A (FOXA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Fox Corp Class A — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Fox Corp Class A trades at $53.77 (market cap $21.80B). The key difference: Fox Corp Class A is far larger — about 4.9× ACADIA Pharmaceuticals Inc.'s market cap, and Fox Corp Class A pays a 1.02% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | FOXA | |
|---|---|---|
Market Cap | $4.49B | $21.80B |
Sector | Health | Media |
52-Week High | $28.06 | $76.11 |
52-Week Low | $20.06 | $48.79 |
Enterprise Value | $3.69B | $25.77B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FOXA trades at $55.87, down 1.08% with bearish technical signals despite strong fundamentals. The company reported robust earnings with Q1 2026 EPS of $1.32 beating expectations by 29%, continuing a trend of quarterly beats. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. However, the stock faces headwinds from the recent $22B Roku acquisition announcement, which has raised leverage concerns and contributed to recent price weakness.
The outlook remains balanced with 50% analyst buy ratings and a $67.80 consensus target suggesting 21% upside potential. Key risks include integration challenges from the Roku acquisition and streaming competition, while opportunities lie in advertising growth from World Cup events and Tubi streaming momentum. Valuation appears reasonable with P/E of 14.7x and EV/EBITDA of 8.4x.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
